Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group.
Barcellini A, Golia D'Augè T, Mandato VD, Cuccu I, Musella A, Fruscio R, Vitale MG, Martinello R, Mangili G, Pignata S, Palaia I. Barcellini A, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2024 Jan;193:104201. doi: 10.1016/j.critrevonc.2023.104201. Epub 2023 Nov 17. Crit Rev Oncol Hematol. 2024. PMID: 37977312 Free article. Review.
Ovarian cancer in the elderly.
Pignata S, Vermorken JB. Pignata S, et al. Crit Rev Oncol Hematol. 2004 Jan;49(1):77-86. doi: 10.1016/s1040-8428(03)00100-8. Crit Rev Oncol Hematol. 2004. PMID: 14734157 Review.
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F. Pignata S, et al. Crit Rev Oncol Hematol. 2008 Jun;66(3):229-36. doi: 10.1016/j.critrevonc.2007.12.005. Epub 2008 Feb 1. Crit Rev Oncol Hematol. 2008. PMID: 18243011 Clinical Trial.
Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.
Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M. Bellati F, et al. Among authors: pignata s. Crit Rev Oncol Hematol. 2012 Jul;83(1):35-46. doi: 10.1016/j.critrevonc.2011.09.006. Epub 2011 Nov 4. Crit Rev Oncol Hematol. 2012. PMID: 22056314 Review.
Olaparib, PARP1 inhibitor in ovarian cancer.
Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P. Marchetti C, et al. Among authors: pignata s. Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. doi: 10.1517/13543784.2012.707189. Epub 2012 Jul 13. Expert Opin Investig Drugs. 2012. PMID: 22788971 Review.
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Esposito F, et al. Among authors: pignata s. Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12. Oncology. 2014. PMID: 24942520
453 results